Virtus ETF Advisers LLC Purchases New Stake in Neuronetics Inc (STIM)

Virtus ETF Advisers LLC purchased a new stake in Neuronetics Inc (NASDAQ:STIM) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 15,272 shares of the company’s stock, valued at approximately $296,000. Virtus ETF Advisers LLC owned about 0.09% of Neuronetics as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the company. Capital Research Global Investors grew its position in shares of Neuronetics by 26.6% in the third quarter. Capital Research Global Investors now owns 474,644 shares of the company’s stock valued at $15,217,000 after purchasing an additional 99,644 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Neuronetics by 31.7% in the third quarter. Franklin Resources Inc. now owns 412,600 shares of the company’s stock valued at $13,228,000 after purchasing an additional 99,300 shares during the last quarter. BlackRock Inc. grew its position in shares of Neuronetics by 16,237.6% in the third quarter. BlackRock Inc. now owns 408,440 shares of the company’s stock valued at $13,095,000 after purchasing an additional 405,940 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Neuronetics by 19.5% in the third quarter. Wells Fargo & Company MN now owns 347,223 shares of the company’s stock valued at $11,131,000 after purchasing an additional 56,583 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of Neuronetics by 706.2% in the third quarter. Point72 Asset Management L.P. now owns 241,852 shares of the company’s stock valued at $7,754,000 after purchasing an additional 211,852 shares during the last quarter. 69.19% of the stock is currently owned by institutional investors.

Several equities research analysts have recently issued reports on the company. Zacks Investment Research raised Neuronetics from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research report on Saturday, November 10th. BTIG Research reissued a “buy” rating and set a $33.00 target price on shares of Neuronetics in a research report on Wednesday, November 7th. Six analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus target price of $34.50.

STIM stock traded down $0.27 during trading on Wednesday, reaching $17.32. 3,262 shares of the stock were exchanged, compared to its average volume of 118,617. Neuronetics Inc has a twelve month low of $13.26 and a twelve month high of $39.39. The company has a debt-to-equity ratio of 0.33, a current ratio of 7.63 and a quick ratio of 7.46.

WARNING: This news story was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2019/02/13/virtus-etf-advisers-llc-purchases-new-stake-in-neuronetics-inc-stim.html.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.

Recommended Story: Why do companies issue convertible shares?

Institutional Ownership by Quarter for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply